# US 2021/0228780 A1 · Drug-coated balloon catheters for body lumens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0228780 A1
- Document ID: US20210228780A1
- Status: Published application
- Kind: A1
- Application number: 17/208,561
- Filed: 2021-03-22
- Published: 2021-07-29
- Earliest claimed: 2012-10-26
- Assignees: Urotronic, Inc.
- Applicants: Urotronic, Inc.
- Inventors: Lixiao Wang; Peter Barnett; David Hendrickson
- Web page: https://patentgrep.com/patent/US20210228780A1

## CPC

- A61L 29/08: Materials for coatings
- A61L 29/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 29/085: {Macromolecular materials}
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61M 25/1002: {characterised by balloon shape (A61M25/1006, A61M25/1009 take precedence)}
- A61M 25/10185: {Valves}
- A61M 29/02: Dilators made of swellable material {(balloon catheters for angioplasty A61M25/104)}
- A61B 1/307: for the urinary organs, e.g. urethroscopes or cystoscopes
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/426: Immunomodulating agents, i.e. cytokines, interleukins, interferons
- A61M 2025/105: {having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes}
- A61M 2025/1075: {having a balloon composed of several layers, e.g. by coating or embedding}
- A61M 2202/0488: Surfactant, e.g. for the lung
- A61M 2205/0205: Materials having antiseptic or antimicrobial properties, e.g. silver compounds, rubber with sterilising agent
- A61M 2210/0681: Sinus (maxillaris)
- A61M 2210/1032: Trachea
- A61M 2210/1039: Lungs
- A61M 2210/105: Oesophagus
- A61M 2210/1053: Stomach
- A61M 2210/1057: Duodenum
- A61M 2210/106: Small intestine
- A61M 2210/1064: Large intestine
- A61M 2210/1078: Urinary tract
- A61M 2210/1085: Bladder
- A61M 2210/1096: Male
- A61M 2210/166: Prostate
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

## Claims

### Claim 1

A drug-coated balloon catheter comprising:
an elongated balloon having a nominal diameter of 4 mm to 50 mm and a length of 20 mm to 160 mm; and
a coating layer overlaying an exterior surface of the balloon, the coating layer comprising
an initial drug load of a therapeutic agent, the therapeutic agent comprising paclitaxel, a paclitaxel analogue, docetaxel, a docetaxel analogue, taxol, a taxol analogue, rapamycin, a rapamycin analogue, sirolimus, a sirolimus analogue, everolimus, an everolimus analogue, tacrolimus, a tacrolimus analogue, mammalian target of rapamycin (mTOR) inhibitors, an mTOR inhibitor analogue, or a combination thereof, and
one or more additives, wherein a ratio of the therapeutic agent to the one or more additives in the coating layer is 0.1 to 10;
wherein a soaking procedure for treating a target site in a body lumen with the drug-coated balloon catheter is sufficient for the coating layer to release 37 wt % to 97 wt % of the initial drug load of the therapeutic agent from the coating layer, wherein the soaking procedure consists of
passing the drug-coated balloon catheter through an introducer sheath into a cylindrical vessel, the cylindrical vessel comprising 0.9% saline at 37° C.,
soaking the drug-coated balloon catheter in the saline in the cylindrical vessel for 1 minute,
inflating the drug-coated balloon catheter for 1 minute, and
withdrawing the drug-coated balloon catheter from the cylinder.

### Claim 2 (depends on 1)

The drug-coated balloon catheter of claim 1, wherein the initial drug load of the therapeutic agent is from 1 microgram to 20 micrograms per square millimeter of the balloon at the nominal diameter of the balloon.

### Claim 3 (depends on 1)

The drug-coated balloon catheter of claim 1, wherein a ratio by weight of the therapeutic agent to the total weight of the one or more additives in the coating layer is from 0.1 to 5.

### Claim 4 (depends on 1)

The drug-coated balloon catheter of claim 1, wherein a ratio by weight of the therapeutic agent to the total weight of the one or more additives in the coating layer is from 2 to 6.

### Claim 5 (depends on 1)

The drug-coated balloon catheter of claim 1, wherein the initial drug load of the therapeutic agent is from 1 microgram to 20 micrograms per square millimeter of the balloon at the nominal diameter of the balloon.

### Claim 6 (depends on 1)

The drug-coated balloon catheter of claim 1, wherein the one or more additives in the coating layer comprise one or more water-soluble additives.

### Claim 7 (depends on 1)

The drug-coated balloon catheter of claim 1, wherein the one or more additives in the coating layer comprise one or more surfactants.

### Claim 8 (depends on 7)

The drug-coated balloon catheter of claim 7, wherein the surfactant is a nonionic, anionic, cationic, or zwitterionic surfactant.

### Claim 9 (depends on 8)

The drug-coated balloon catheter of claim 8, wherein the surfactant is a quaternary ammonium salt, a fatty acid salt, a bile salt, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, docecyl trimethyl ammonium bromide, sodium docecylsulfates, dialkyl methylbenzyl ammonium chloride, edrophonium chloride, domiphen bromide, dialkylester of sodium sulfonsuccinic acid, sodium dioctyl sulfosuccinate, sodium cholate, sodium taurocholate, or a combination thereof.

### Claim 10 (depends on 1)

The drug-coated balloon catheter of claim 1, wherein the one or more additives in the coating layer comprise one or more sterols and/or sterol derivatives.

### Claim 11 (depends on 10)

The drug-coated balloon catheter of claim 10, wherein the one or more sterols and/or sterol derivatives comprise PEG-24 cholesterol ether.

### Claim 12 (depends on 1)

The drug-coated balloon catheter of claim 1, wherein the one or more additives in the coating layer comprise one or more polymers.

### Claim 13 (depends on 1)

The drug-coated balloon catheter of claim 1, wherein the one or more additives in the coating layer comprise
a polymer, and
a sterol and/or sterol derivative.

### Claim 14 (depends on 1)

The drug-coated balloon catheter of claim 1, wherein the one or more additives in the coating layer comprise a polymer and a surfactant.

### Claim 15 (depends on 1)

The drug-coated balloon catheter of claim 1, wherein the drug-coated balloon catheter further comprises an adherent layer between the exterior surface of the balloon and the coating layer, wherein the adherent layer improves the adherence of the coating layer to the exterior surface of the balloon.

### Claim 16

A drug-coated balloon catheter comprising:
an elongated balloon having a nominal diameter of 4 mm to 50 mm and a length of 20 mm to 160 mm; and
a coating layer overlaying an exterior surface of the balloon, the coating layer comprising
an initial drug load of a therapeutic agent, the therapeutic agent comprising paclitaxel, a paclitaxel analogue, docetaxel, a docetaxel analogue, taxol, a taxol analogue, rapamycin, a rapamycin analogue, sirolimus, a sirolimus analogue, everolimus, an everolimus analogue, tacrolimus, a tacrolimus analogue, mammalian target of rapamycin (mTOR) inhibitors, an mTOR inhibitor analogue, or a combination thereof, and
one or more additives, wherein a ratio of the therapeutic agent to the one or more additives in the coating layer is 0.1 to 10;
wherein a treatment procedure for treating a target site in a body lumen with the drug-coated balloon catheter is sufficient for the coating layer to release more than 30 wt % of the initial drug load of the therapeutic agent from the coating layer to the target site in the body lumen, wherein the treatment procedure consists of
flushing the target site in the body lumen with a flushing media comprising water, saline solution, or a water solution comprising at least one water-soluble additive,
inserting the drug-coated balloon catheter into the body lumen such that the drug-coated balloon catheter is at the target site in the body lumen,
holding the drug-coated balloon catheter in position at the target site for a soaking period of at least 1 minute prior to inflation to hydrate the coating layer in the flushing media,
inflating the drug-coated balloon catheter to contact walls of the body lumen at the target site with the coating layer for an inflation period of 0.1 minute to 10 minutes,
deflating the drug-coated balloon catheter, and
withdrawing the drug-coated balloon catheter from the target site.

### Claim 17 (depends on 16)

The drug-coated balloon catheter of claim 16, wherein the treatment procedure is sufficient for the coating layer to release 37%-97% of the initial drug load to the target site in the body lumen.

### Claim 18 (depends on 16)

The drug-coated balloon catheter of claim 16, wherein a ratio by weight of the therapeutic agent to the total weight of the one or more additives in the coating layer is from 0.1 to 5.

### Claim 19 (depends on 16)

The drug-coated balloon catheter of claim 16, wherein the body lumen comprises a vascular lumen, a nonvascular lumen, a coronary artery, a peripheral artery, a prostatic urethra, a urethra, a ureter, an esophagus, a biliary tract, a stomach, a small intestine, a duodenum, a jejunum, an ileum, a colon, a rectum, a large intestine, a sinus, or a bronchial airway.

### Claim 20 (depends on 16)

The drug-coated balloon catheter of claim 16, wherein the initial drug load of the therapeutic agent is from 1 microgram to 20 micrograms per square millimeter of the balloon at the nominal diameter of the balloon.

### Claim 21

A drug-coated balloon catheter comprising:
an elongated balloon having a nominal diameter of 4 mm to 50 mm and a length of 20 mm to 160 mm; and
a coating layer overlaying an exterior surface of the balloon, the coating layer comprising
an initial drug load of a therapeutic agent of 1 micrograms to 20 micrograms of a therapeutic agent per square millimeter of the balloon at the nominal diameter of the balloon, the therapeutic agent comprising paclitaxel, a paclitaxel analogue, docetaxel, a docetaxel analogue, taxol, a taxol analogue, rapamycin, a rapamycin analogue, sirolimus, a sirolimus analogue, everolimus, an everolimus analogue, tacrolimus, a tacrolimus analogue, mammalian target of rapamycin (mTOR) inhibitors, an mTOR inhibitor analogue, or a combination thereof, and
one or more additives, wherein a ratio of the therapeutic agent to the one or more additives in the coating layer is 0.1 to 10;
wherein a treatment procedure for treating a target site in a body lumen with the drug-coated balloon catheter is sufficient for the coating layer to release the therapeutic agent from the coating layer into body lumen tissue at the target site such that the body lumen tissue at the target site have a concentration of the therapeutic agent of 0.083 μg/g to 582 μg/g at 1 day, wherein the treatment procedure consists of
flushing the target site in the body lumen with a flushing media comprising water, saline solution, or a water solution comprising at least one water-soluble additive,
inserting the drug-coated balloon catheter into the body lumen such that the drug-coated balloon catheter is at the target site in the body lumen,
holding the drug-coated balloon catheter in position at the target site for a soaking period of at least 1 minute prior to inflation to hydrate the coating layer in the flushing media,
inflating the drug-coated balloon catheter to contact walls of the body lumen at the target site with the coating layer for an inflation period of 0.1 minute to 10 minutes,
deflating the drug-coated balloon catheter, and
withdrawing the drug-coated balloon catheter from the target site.

### Claim 22 (depends on 21)

The drug-coated balloon catheter of claim 21, wherein the treatment procedure is sufficient for the coating layer to release the therapeutic agent from the coating layer into body lumen tissue at the target site such that the body lumen tissue at the target site have a concentration of the therapeutic agent of 0.003 μg/g to 62 μg/g at 7 days.

### Claim 23 (depends on 21)

The drug-coated balloon catheter of claim 21, wherein the treatment procedure is sufficient for the coating layer to release the therapeutic agent from the coating layer into body lumen tissue at the target site such that the body lumen tissue at the target site have a concentration of the therapeutic agent of 0.025 μg/g to 33 μg/g at 28 days.

### Claim 24 (depends on 21)

The drug-coated balloon catheter of claim 21, wherein a ratio by weight of the therapeutic agent to the total weight of the one or more additives in the coating layer is from 0.1 to 5.

### Claim 25

A drug-coated balloon catheter comprising:
an elongated balloon having a nominal diameter of 4 mm to 50 mm and a length of 20 mm to 160 mm; and
a coating layer overlaying an exterior surface of the balloon, the coating layer comprising
an initial drug load of a therapeutic agent, the therapeutic agent comprising paclitaxel, a paclitaxel analogue, docetaxel, a docetaxel analogue, taxol, a taxol analogue, rapamycin, a rapamycin analogue, sirolimus, a sirolimus analogue, everolimus, an everolimus analogue, tacrolimus, a tacrolimus analogue, mammalian target of rapamycin (mTOR) inhibitors, an mTOR inhibitor analogue, or a combination thereof, and
one or more additives, wherein a ratio of the therapeutic agent to the one or more additives in the coating layer is 0.1 to 10;
wherein a treatment procedure for treating a target site in a body lumen with the drug-coated balloon catheter is sufficient for the coating layer to release 0.1% to 25% of the initial drug load of the therapeutic agent from the coating layer to a body lumen wall at the target site in the body lumen, wherein the treatment procedure consists of
flushing the target site in the body lumen with a flushing media comprising water, saline solution, or a water solution comprising at least one water-soluble additive,
inserting the drug-coated balloon catheter into the body lumen such that the drug-coated balloon catheter is at the target site in the body lumen,
holding the drug-coated balloon catheter in position at the target site for a soaking period of at least 1 minute prior to inflation to hydrate the coating layer in the flushing media,
inflating the drug-coated balloon catheter to contact the body lumen wall at the target site with the coating layer for an inflation period of 0.1 minute to 10 minutes,
deflating the drug-coated balloon catheter, and
withdrawing the drug-coated balloon catheter from the target site.

### Claim 26 (depends on 25)

The drug-coated balloon catheter of claim 25, wherein the initial drug load of the therapeutic agent is from 1 microgram to 20 micrograms per square millimeter of the balloon at the nominal diameter of the balloon.

### Claim 27 (depends on 25)

The drug-coated balloon catheter of claim 25, wherein a ratio by weight of the therapeutic agent to the total weight of the one or more additives in the coating layer is from 0.1 to 5.
